Physicians' Academy for Cardiovascular Education

Beneficial effects of SGLT2 inhibitor in diabetic patients with metabolic syndrome

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome

Literature - Davies MJ, Merton KW, Vijapurkar U, et al. - Diabetes Metab Syndr Obes. 2017;10:47-55

Main results


In a post-hoc analysis of two studies, canagliflozin had beneficial effects on body weight, BMI, waist circumference, SBP, DBP and HDL-C compared with glimepiride or sitagliptin in T2DM patients with metabolic syndrome. In the overall study populations, canagliflozin was generally well tolerated, with a higher incidence of genital mycotic infections and osmotic diuresis–related AEs.


Show references

Find this article online at Diabetes Metab Syndr Obes

Share this page with your colleagues and friends: